US corporate heavyweights take lead on Sanofi’s $12bn pharma deal
Weil Gotshal & Manges and Paul Weiss Rifkind Wharton & Garrison have led on Sanofi’s $11.6bn deal with Bioverativ, after losing out on a string of potential acquisitions in recent years.